Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Ocular Therapeutix to post earnings of ($0.40) per share and revenue of $13.2010 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.
Ocular Therapeutix Stock Up 1.5%
Shares of NASDAQ:OCUL opened at $8.64 on Tuesday. The business’s 50 day simple moving average is $9.13 and its two-hundred day simple moving average is $9.26. The firm has a market cap of $1.89 billion, a P/E ratio of -5.92 and a beta of 0.88. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. Ocular Therapeutix has a 52-week low of $6.23 and a 52-week high of $16.44.
Insider Buying and Selling at Ocular Therapeutix
In other news, insider Pravin Dugel sold 21,156 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total value of $173,479.20. Following the transaction, the insider owned 2,597,170 shares in the company, valued at $21,296,794. This trade represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 28,999 shares of company stock valued at $237,792 in the last 90 days. 3.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On Ocular Therapeutix
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the company. Zacks Research downgraded Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Robert W. Baird upped their price objective on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Royal Bank Of Canada reiterated an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, May 6th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Twelve analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $25.11.
Read Our Latest Report on OCUL
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
Featured Articles
- Five stocks we like better than Ocular Therapeutix
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
- Wintrust: A Quiet Regional Bank Posting Loud Results
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
